We are live on ! Find out more
RYZB

RayzeBio, Inc. Common Stock
RYZB

Delisted

RYZB was delisted on the 23rd of February, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in RayzeBio, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 107 → 0 (-107)

100% less funds holding in top 10

Funds holding in top 10: 18 → 0 (-18)

100% less capital invested

Capital invested by funds: $3.41B → $0 (-$3.41B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 106

Holders
–
Holders Change
-107
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-18
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
106
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$413M
2
VP
venBio Partners
California
-$321M
3
VVM
Versant Venture Management
California
-$321M
4
VA
VR Adviser
New York
-$251M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$216M
Name Holding Trade Value Shares
Change 		Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
– -$413M -6,642,700 Closed
VP
2
venBio Partners
California
– -$321M -5,158,162 Closed
VVM
3
Versant Venture Management
California
– -$321M -5,158,161 Closed
VA
4
VR Adviser
New York
– -$251M -4,030,471 Closed
Wellington Management Group
5
Wellington Management Group
Massachusetts
– -$216M -3,504,409 Closed
SI
6
Sofinnova Investments
California
– -$150M -2,419,528 Closed
O
7
OrbiMed
New York
– -$147M -2,365,213 Closed
RG
8
Redmile Group
California
– -$115M -1,857,706 Closed
SB
9
Samsara BioCapital
California
– -$115M -1,845,948 Closed
BlackRock
10
BlackRock
New York
– -$85.1M -1,368,838 Closed
FFM
11
Fairmount Funds Management
Pennsylvania
– -$77.5M -1,245,929 Closed
CAM
12
Cormorant Asset Management
Massachusetts
– -$75.4M -1,213,478 Closed
Vanguard Group
13
Vanguard Group
Pennsylvania
– -$72.7M -1,169,984 Closed
HA
14
HHLR Advisors
Cayman Islands
– -$66M -1,062,383 Closed
DM
15
Deerfield Management
New York
– -$62.6M -1,006,126 Closed
AllianceBernstein
16
AllianceBernstein
Tennessee
– -$58.4M -938,877 Closed
TCM
17
TCG Crossover Management
California
– -$54.1M -869,908 Closed
AWGLSCP
18
ABG-WTT Global Life Science Capital Partners
Hong Kong
– -$48.4M -778,922 Closed
SCV
19
Sands Capital Ventures
Virginia
– -$48.4M -778,922 Closed
LCM
20
Laurion Capital Management
New York
– -$48M -771,913 Closed
AAM
21
Alpine Associates Management
Florida
– -$47.4M -762,900 Closed
SCM
22
Soleus Capital Management
Connecticut
– -$46.4M -746,622 Closed
PA
23
Perceptive Advisors
New York
– -$46.3M -744,056 Closed
LGM
24
Logos Global Management
California
– -$35.3M -568,173 Closed
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
– -$33.6M -539,793 Closed
1
2 3 4 5

RYZB Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in RayzeBio, Inc. Common Stock (RYZB) for Q1 2024, worth a combined $0 — down 100% from $3.41B a quarter earlier.

Sellers outnumbered buyers: 106 funds closed out of RYZB and 0 opened new positions — a net loss of 106 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Viking Global Investors, exiting entirely with an estimated $413M sold.

  • 0 institutional investors held RayzeBio, Inc. Common Stock (RYZB) as of Q1 2024, down from 107 in Q4 2023.
  • Funds reported $0 of RayzeBio, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new RayzeBio, Inc. Common Stock positions in Q1 2024 and 106 closed out, a net change of -106 holders.
  • The largest RayzeBio, Inc. Common Stock seller in Q1 2024 was Viking Global Investors, an estimated $413M sold.

Based on aggregated 13F filings for Q1 2024.